Medtronic (NYSE:MDT – Get Free Report) is expected to be announcing its Q1 2027 results before the market opens on Tuesday, September 1st. Analysts expect Medtronic to post earnings of $1.39 per share and revenue of $9.5458 billion for the quarter. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. Parties may review the information on the company’s upcoming Q1 2027 earning report page for the latest details on the call scheduled for Tuesday, September 1, 2026 at 7:45 AM ET.
Medtronic (NYSE:MDT – Get Free Report) last issued its quarterly earnings data on Wednesday, June 3rd. The medical technology company reported $1.55 EPS for the quarter, beating analysts’ consensus estimates of $1.54 by $0.01. Medtronic had a return on equity of 14.51% and a net margin of 13.20%.The firm had revenue of $9.81 billion for the quarter, compared to analyst estimates of $9.62 billion. During the same period in the prior year, the firm posted $1.62 EPS. The company’s revenue for the quarter was up 9.9% on a year-over-year basis. On average, analysts expect Medtronic to post $6 EPS for the current fiscal year and $6 EPS for the next fiscal year.
Medtronic Price Performance
NYSE:MDT opened at $91.28 on Monday. Medtronic has a 52 week low of $73.31 and a 52 week high of $106.33. The company has a debt-to-equity ratio of 0.52, a quick ratio of 1.62 and a current ratio of 2.13. The firm’s 50-day simple moving average is $85.57 and its 200 day simple moving average is $85.56. The firm has a market cap of $116.84 billion, a price-to-earnings ratio of 24.47, a P/E/G ratio of 2.45 and a beta of 0.55.
Medtronic Announces Dividend
Analyst Ratings Changes
A number of brokerages have weighed in on MDT. Piper Sandler reaffirmed a “neutral” rating on shares of Medtronic in a report on Monday, August 10th. Wall Street Zen raised Medtronic from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Stifel Nicolaus set a $80.00 target price on Medtronic in a research note on Wednesday, June 3rd. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $118.00 price target on shares of Medtronic in a report on Thursday, June 4th. Finally, Deutsche Bank Aktiengesellschaft lowered their price objective on shares of Medtronic from $100.00 to $78.00 and set a “hold” rating for the company in a research report on Thursday, June 4th. Eighteen investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $99.79.
View Our Latest Stock Analysis on Medtronic
Insider Buying and Selling
In related news, EVP Harry Skip Kiil sold 4,189 shares of the firm’s stock in a transaction on Monday, June 8th. The stock was sold at an average price of $80.44, for a total transaction of $336,963.16. Following the completion of the transaction, the executive vice president directly owned 37,227 shares of the company’s stock, valued at $2,994,539.88. This trade represents a 10.11% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.27% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Acumen Wealth Advisors LLC bought a new stake in Medtronic in the fourth quarter worth approximately $29,000. Imprint Wealth LLC acquired a new stake in shares of Medtronic during the 3rd quarter worth approximately $31,000. Chapman Financial Group LLC acquired a new stake in shares of Medtronic during the 2nd quarter worth approximately $37,000. JPL Wealth Management LLC acquired a new stake in shares of Medtronic during the 3rd quarter worth approximately $40,000. Finally, Caitong International Asset Management Co. Ltd increased its stake in shares of Medtronic by 96.5% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 454 shares of the medical technology company’s stock valued at $44,000 after acquiring an additional 223 shares in the last quarter. 82.06% of the stock is owned by institutional investors and hedge funds.
Key Stories Impacting Medtronic
Here are the key news stories impacting Medtronic this week:
- Positive Sentiment: Needham raised its price target to $114 from $101 and reiterated a “Buy” rating, implying substantial upside from recent trading levels. The firm reportedly expects Medtronic to beat first-quarter estimates and raise its fiscal 2027 guidance. Needham raises Medtronic price target
- Positive Sentiment: Analysts see potential for Medtronic to exceed consensus first-quarter expectations of approximately $1.39 in adjusted EPS and $9.54 billion in revenue. A stronger-than-expected report could support the shares, particularly if management lifts its fiscal 2027 outlook. Medtronic earnings estimates
- Positive Sentiment: Recent coverage highlights momentum in Medtronic’s cardiovascular businesses and growth in renal denervation, while broader device demand is supporting the company’s rebound narrative. Medtronic device momentum
- Neutral Sentiment: The imminent earnings release is likely to keep volatility elevated. Investors will evaluate quarterly performance, procedure trends, and management’s fiscal 2027 guidance for confirmation that the recovery is sustainable. Medtronic rebound outlook
- Negative Sentiment: Tariff exposure and unfavorable currency movements remain potential headwinds to margins and reported growth. These risks could limit the benefit of strong cardiovascular trends or weigh on the shares if management issues cautious guidance. Medtronic portfolio outlook
Medtronic Company Profile
Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.
Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).
Read More
- Five stocks we like better than Medtronic
- Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally
- Rubrik’s AI Security Bet Could Power the Next Leg Higher
- Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All
- Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against?
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.
